Combination therapy for treatment of germline BRCA-mutated metastatic breast cancer

August 18, 2020

Results from the study showed antitumor activity and safety to be similar to olaparib and durvalumab monotherapy outcomes.

New findings from a MEDIOLA trial found that the combination of Olaparib and durvalumab in treating germline BRCA1-mutated or BRCA2-mutated metastatic breast cancer had similar results to those previously observed in monotherapy studies of both Olaparib and durvalumab.

The study’s authors noted the promising antitumor activity and safety of this combination therapy but call for further research via a randomized controlled trial to determine therapeutic and long-term clinical benefits.

For further details on the study and its findings, visit Drug Topics.